Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes

References

• Matsushita K, van der Velde M, Astor BC et al.; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731), 2073–2081 (2010).
   PubMed Web of Science ®Google Scholar
• van der Velde M, Matsushita K, Coresh J et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 79(12), 1341–1352 (2011).
   PubMedGoogle Scholar
• Gansevoort RT, Matsushita K, van der Velde M et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 80(1), 93–104 (2011).
   PubMed Web of Science ®Google Scholar
• Hemmelgarn BR, Manns BJ, Lloyd A et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303(5), 423–429 (2010).
   PubMed Web of Science ®Google Scholar
• Bello AK, Hemmelgarn B, Lloyd A et al.; Alberta Kidney Disease Network. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 6(6), 1418–1426 (2011).
   PubMed Web of Science ®Google Scholar
• Muntner P, Bowling CB, Gao L et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin. J. Am. Soc. Nephrol. 6(9), 2200–2207 (2011).
   PubMed Web of Science ®Google Scholar
• Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80(1), 17–28 (2011).
   PubMed Web of Science ®Google Scholar
• Tonelli M, Muntner P, Lloyd A et al.; Alberta Kidney Disease Network. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann. Intern. Med. 154(1), 12–21 (2011).
   PubMed Web of Science ®Google Scholar
• Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J. Am. Soc. Nephrol. 19(9), 1785–1791 (2008).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mann JF, Schumacher H et al.; ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22(7), 1353–1364 (2011).
   PubMed Web of Science ®Google Scholar
• Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J. Hypertens. 28(10), 1983–1994 (2010).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351(19), 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Bilous R, Chaturvedi N, Sjølie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med. 151(1), 11–20, W3 (2009).
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, Dyal L et al.; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann. Intern. Med. 151(1), 1–10, W1 (2009).
   PubMed Web of Science ®Google Scholar
• Mauer M, Zinman B, Gardiner R et al. Renal and retinal effects of enalapril and losartan in Type 1 diabetes. N. Engl. J. Med. 361(1), 40–51 (2009).
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL Jr et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 364(10), 907–917 (2011).
   PubMed Web of Science ®Google Scholar
• Haller H, Viberti GC, Mimran A et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J. Hypertens. 24(2), 403–408 (2006).
   PubMed Web of Science ®Google Scholar
• Ritz E, Viberti GC, Ruilope LM et al. Determinants of urinary albumin excretion within the normal range in patients with Type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 53(1), 49–57 (2010).
   PubMedGoogle Scholar
• Menne J, Izzo JL Jr, Ito S et al.; ROADMAP investigators. Prevention of microalbuminuria in patients with Type 2 diabetes and hypertension. J. Hypertens. 30(4), 811–818; discussion 818 (2012).
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with Type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378(9786), 156–167 (2011).
   PubMed Web of Science ®Google Scholar
• Seshasai SR, Kaptoge S, Thompson A et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364(9), 829–841 (2011).
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am. Heart J. 161(1), 210–219.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann. Intern. Med. 144(12), 884–893 (2006).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Wun CC et al.; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur. Heart J. 31(23), 2897–2908 (2010).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 122(21), 2142–2151 (2010).
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P et al.; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 27(7), 1360–1369 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
   PubMed Web of Science ®Google Scholar
• Mann JF, Gerstein HC, Yi QL et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J. Am. Soc. Nephrol. 14(3), 641–647 (2003).
   PubMed Web of Science ®Google Scholar
• de Galan BE, Perkovic V, Ninomiya T et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in Type 2 diabetes. J. Am. Soc. Nephrol. 20(4), 883–892 (2009).
   PubMedGoogle Scholar